X4 Pharmaceuticals (XFOR) Misses Q1 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
May 6, 2021 8:00 AM EDTCompany continues to make significant clinical progress with lead candidate mavorixafor across multiple rare disease indications
Enrollment update on Phase 3 WHIM trial expected in mid-2021
Initial data from ongoing Phase 1b trial in Waldenströms macroglobulinemia to be presented at EHA Meeting in June 2021
Conference call today at 8:30 a.m. ET
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq:... More
